BJDX
Bluejay Diagnostics, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.70
−6.46%Oct 13, 2026, 10:30 UTC
Bluejay Diagnostics completed establishment of a manufacturing site for Symphony cartridges, meeting a contractual milestone under its amended license agreement with Toray Industries.
Source:Oct 6, 2026, 10:30 UTC
Bluejay Diagnostics announced baseline clinical characteristics from its SYMON-II clinical validation study, covering 777 evaluable patients, as it advances the Symphony IL-6 Test toward regulatory submission.
Sep 8, 2026, 10:30 UTC
Bluejay Diagnostics and Lovell Government Services announced a partnership to expand access to U.S. federal healthcare markets, establishing a federal distribution and co-marketing framework across VA, DoD, Military Health Systems and other government healthcare channels.
Source:Aug 13, 2026, 10:00 UTC
Bluejay Diagnostics reported its financial results for the quarter ended June 30, 2026, and provided an update on clinical, regulatory and manufacturing progress, including advancement of its Symphony IL-6 test toward regulatory submission and commercialization.
Source:Jul 21, 2026, 10:30 UTC
Bluejay Diagnostics completed enrollment of 750 patients in the SYMON-II clinical validation study for its Symphony IL-6 sepsis test ahead of schedule.
Source:Jun 9, 2026, 00:00 UTC
Bluejay Diagnostics, Inc. elected Donald Chase, Neil Dey, Svetlana Dey, Douglas Wurth, and Fred Zeidman as directors, effective June 9, 2026.
Jun 3, 2026, 15:48 UTC
Bluejay Diagnostics disclosed a private placement to raise up to $23.6 million.
Source:Jun 2, 2026, 00:00 UTC
Bluejay Diagnostics signed a manufacturing services agreement with Argonaut Manufacturing Services for its IL-6 testing products supporting the Symphony platform.
Source: